The future of psychopharmacology of depression.
The DOI matches its Crossref record.
Abstract
Article AbstractThere are clear limitations to the currently approved pharmacotherapies of depression, including the fact that they are all essentially monoamine-based, have modest efficacy and a relatively slow onset of efficacy, and suffer from significant tolerability issues, particularly in the long term, including sexual dysfunction, weight gain, and cognitive impairments. This article reviews some of the most promising novel mechanisms that are not represented in compounds currently approved for depression in either the United States or Europe and that may represent the future of the psychopharmacologic treatment of depression, potentially addressing some of the efficacy and tolerability issues of antidepressants on the market. These potential antidepressant treatments include the multimodal serotonergic agents, the triple uptake inhibitors, the neurokinin-based novel therapies, the glutamatergic treatments, the nicotinic receptor-based treatments, the neurogenesis-based treatments, and antiglucocorticoid therapies. Some of these mechanisms appear to be more advanced in terms of drug development than others, but they all contribute to the global effort to develop more effective and better tolerated treatments for major depressive disorder.J Clin Psychiatry 2010;71(8):971-975Submitted: May 5, 2010; accepted June 17, 2010 (doi:10.4088/JCP.10m06223blu). Corresponding author: Maurizio Fava, MD, Depression Clinical and Research Program, Massachusetts General Hospital, 55 Fruit St, Bulfinch 351, Boston, MA 02114 (MFava@Partners.org).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
“This new generation of antidepressant is suggested to have comparable antidepressant efficacy to other drug classes, but is more tolerable (for review Chang and Fava, 2010).”
BackgroundBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.14530 · Cited by 545
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Fagiolini, A., Comandini, A., Dell’Osso, M. C., & Kasper, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0010-5 · Cited by 228
“SSRIs and their derivative compounds, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) and noradrenaline reuptake inhibitors (NERIs), have since been shown to be comparable in efficacy and more tolerable than older agents such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors…”
Background
Metadata
- Authors
- Chang, T., & Fava, M.
- Affiliations
- Massachusetts General Hospital (US)
- ORCID
- Chang, Trina
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-08-15
- Volume
- 71
- Issue
- 08
- Pages
- 971-975
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034147634
- Semantic Scholar
- d6d3f91d58f90222f3bf16c9a0e933fdb631ec3e
- Cited by
- 50
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 7 · 2014: 3 · 2013: 2 · 2012: 9
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (T32MH19126, T32MH019126)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- depression, antidepressants, major depressive disorder, neurokinin receptor antagonists, nicotinic agonists, antidepressant tolerability, sexual dysfunction, weight gain, cognitive impairment
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Depressive Disorder, Europe, Humans, Psychopharmacology, United States, Treatment Outcome, Drug Approval, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The future of psychopharmacology of depression. https://app.cochat.ai/papers/10.4088/jcp.10m06223blu
- The paper
- Chang, T., & Fava, M. (2010). The future of psychopharmacology of depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.10m06223blu
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.